CRBU Stock Analysis: Buy, Sell, or Hold?
CRBU - Caribou Biosciences, Inc. Common Stock
$1.99
0.09 (4.74%)
▲
5d:
+5.85%
30d:
+13.07%
90d:
+25.16%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
CRBU is down 3.2% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 2 OI. Call ratio: 100% View Scanner →
Strength: 6.6/10
Get Alerted When CRBU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRBU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRBU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRBU is currently trading at $1.99, which is considered extended relative to its 30-day fair value range of $1.80 to $1.99.
Technical Outlook: Technically, CRBU is in a strong uptrend. The price is approaching resistance at $2.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.12 (+459.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRBU is in a strong uptrend. The price is approaching resistance at $2.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.12 (+459.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.80 -
$1.99
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 459.0% below Wall St target ($11.12)
Fair Price Analysis
30-Day Fair Range
$1.80 -
$1.99
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.69
Resistance Level
$2.04
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.33
Wall Street Target
$11.13
(+459.0%)
Revenue Growth (YoY)
89.7%
Share & Embed Analysis
Last updated: April 02, 2026 6:10 AM ET
Data refreshes hourly during market hours. Next update: 7:10 AM
Data refreshes hourly during market hours. Next update: 7:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara G Mcclung
SELL
6938 shares
2026-02-24
Ruhi Ahmad Khan
SELL
6938 shares
2026-02-24
Timothy P Kelly
SELL
3147 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |
